Hanno B. Richards

6.7k citations

58 papers · 5.0k indexed · 3 hit papers · h-index 35

Co-authors: Shephard Mpofu Westley H. Reeves Brian Porter Désirée van der Heijde Minoru Satoh Luminita Pricop Iain B. McInnes Jürgen Braun
Topics: Spondyloarthritis Studies and Treatments (26 papers)Psoriasis: Treatment and Pathogenesis (24 papers)Systemic Lupus Erythematosus Research (21 papers)
Cited by: Rheumatology Immunology Hematology
Journals: New England Journal of Medicine The Lancet Journal of Biological Chemistry
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Hanno B. Richards

56 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

2015 732 citations Jürgen Braun, Xenofon Baraliakos et al. profile →
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →

Peers

Countries citing papers authored by Hanno B. Richards

Since Specialization

Citations

This map shows the geographic impact of Hanno B. Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanno B. Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanno B. Richards more than expected).

Fields of papers citing papers by Hanno B. Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanno B. Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanno B. Richards. The network helps show where Hanno B. Richards may publish in the future.

Co-authorship network of co-authors of Hanno B. Richards

This figure shows the co-authorship network connecting the top 25 collaborators of Hanno B. Richards. A scholar is included among the top collaborators of Hanno B. Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanno B. Richards. Hanno B. Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data 2022 ·Acta Dermato Venereologica ·Alice B. Gottlieb,Atul Deodhar,Iain B. McInnes,Xenofon Baraliakos,Kristian Reich,Stefan Schreiber,Weibin Bao,Kwaku Marfo,Hanno B. Richards,Luminita Pricop,Abhijit Shete,Vivek Trivedi,Deborah Keefe,C. Papavassilis,(unknown),P. Papanastasiou,Philip J. Mease,Mark Lebwohl	57
2	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT 2021 ·Arthritis Research & Therapy ·Jürgen Braun,Ricardo Blanco,Helena Marzo‐Ortega,Lianne S. Gensler,Filip Van den Bosch,Stephen Hall,Hideto Kameda,Denis Poddubnyy,Marleen van de Sande,Anna Wiksten,Brian Porter,Abhijit Shete,Hanno B. Richards,Sibylle Haemmerle,Atul Deodhar	21
3	Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis 2019 ·Queensland's institutional digital repository (The University of Queensland) ·Iain B. McInnes,Dafna D. Gladman,Atul Deodhar,Corinne Miceli‐Richard,Peter Nash,Naveed Sattar,Nehal N. Mehta,Darren L. Asquith,(unknown),Hanno B. Richards,Luminita Pricop,Abhijit Shete	1
4	Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study 2018 ·Rheumatology and Therapy ·Alan Kivitz,Ulf Wagner,Eva Dokoupilová,Jerzy Supronik,Ruvie Martin,Zsolt Talloczy,Hanno B. Richards,Brian Porter	83
5	Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study 2017 ·Rheumatology and Therapy ·Hasan Tahir,Atul Deodhar,Mark C. Genovese,Tsutomu Takeuchi,Jacob Aelion,Filip Van den Bosch,Sibylle Haemmerle,Hanno B. Richards	27
6	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis 2016 ·Arthritis & Rheumatology ·Désirée van der Heijde,Robert Landewé,Philip J. Mease,Iain B. McInnes,Philip G. Conaghan,Luminita Pricop,(unknown),Hanno B. Richards,Shephard Mpofu	61
7	Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study 2014 ·Data Archiving and Networked Services (DANS) ·Philip Mease,Iain B. McInnes,Bruce Kirkham,Arthur Kavanaugh,Proton Rahman,Désirée van der Heijde,Robert Landewé,Peter Nash,Luminita Pricop,Jiacheng Yuan,Hanno B. Richards,Shephard Mpofu	12
8	Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial 2014 ·Queensland's institutional digital repository (The University of Queensland) ·Alice B. Gottlieb,Philip Mease,Iain B. McInnes,Bruce Kirkham,Arthur Kavanaugh,Proton Rahman,Peter Nash,Luminita Pricop,Jiacheng Yuan,Hanno B. Richards,Shephard Mpofu	12
9	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study 2014 ·The Journal of Rheumatology ·Mark C. Genovese,Patrick Durez,Hanno B. Richards,Jerzy Supronik,Eva Dokoupilová,Jacob Aelion,Sang‐Heon Lee,Christine E. Codding,Herbert Kellner,Takashi Ikawa,Sophie Hugot,Gregory Ligozio,Shephard Mpofu	83
10	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study 2012 ·Annals of the Rheumatic Diseases ·Mark C. Genovese,Patrick Durez,Hanno B. Richards,Jerzy Supronik,Eva Dokoupilová,Mazurov Vi,Jacob Aelion,Sang‐Heon Lee,Christine E. Codding,Herbert Kellner,Takashi Ikawa,Sophie Hugot,Shephard Mpofu	227
11	Induction of Apoptosis by the Hydrocarbon Oil Pristane: Implications for Pristane-Induced Lupus 2005 ·The Journal of Immunology ·Nicola Calvani,Roberto Caricchio,Marco Tucci,Eric S. Sobel,Franco Silvestris,(unknown),Hanno B. Richards	63
12	Circulating endothelial cells are associated with future vascular events in hemodialysis patients 2005 ·Kidney International ·Mehmet Koç,Hanno B. Richards,Azra Bihorac,Edward A. Ross,Jesse D. Schold,Mark S. Segal	56
13	Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18 2005 ·Autoimmunity Reviews ·Nicola Calvani,Marco Tucci,Hanno B. Richards,(unknown),Franco Silvestris	60
14	The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis 2005 ·Annals of the New York Academy of Sciences ·Marco Tucci,Nicola Calvani,Hanno B. Richards,Cosima Quatraro,Franco Silvestris	40
15	Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis 2004 ·Arthritis & Rheumatism ·Marco Tucci,(unknown),Eric S. Sobel,Byron P. Croker,Mark S. Segal,Westley H. Reeves,Hanno B. Richards	110
16	Nephritogenic autoantibodies but absence of nephritis in Il-12p35–deficient mice with pristane-induced lupus 2003 ·Kidney International ·Nicola Calvani,Minoru Satoh,Byron P. Croker,Westley H. Reeves,Hanno B. Richards	44
17	Effect of an exogenous trigger on the pathogenesis of lupus in (NZB × NZW)F₁ mice 2002 ·Arthritis & Rheumatism ·Hideo Yoshida,Minoru Satoh,(unknown),(unknown),Hanno B. Richards,(unknown),Jun‐Qi Yang,Ram Raj Singh,Westley H. Reeves	43
18	Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus 2001 ·Arthritis & Rheumatism ·(unknown),(unknown),(unknown),Melody Shaw,(unknown),(unknown),(unknown),Xingwen Dong,Robert G. Lahita,Hanno B. Richards,Westley H. Reeves	38
19	Influence of Microbial Stimulation on Hypergammaglobulinemia and Autoantibody Production in Pristane-Induced Lupus 1998 ·Clinical Immunology and Immunopathology ·(unknown),Minoru Satoh,John Swartz,Hanno B. Richards,Westley H. Reeves	43
20	Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus 1998 ·The Journal of Experimental Medicine ·Hanno B. Richards,Minoru Satoh,Melody Shaw,Claude Libert,Valeria Poli,Westley H. Reeves	162

About Hanno B. Richards

Hanno B. Richards is a scholar working on Rheumatology, Immunology and Hematology, having authored 58 papers that have together received 5.0k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (26 papers), Psoriasis: Treatment and Pathogenesis (24 papers) and Systemic Lupus Erythematosus Research (21 papers). The work is most often cited by research in Rheumatology (3.4k citations), Immunology (3.5k citations) and Hematology (1.5k citations). Hanno B. Richards has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Shephard Mpofu, Westley H. Reeves, Brian Porter, Désirée van der Heijde, Minoru Satoh, Luminita Pricop, Iain B. McInnes, Jürgen Braun, Joachim Sieper and Philip J. Mease. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact